CRISPR Therapeutics AG (Premium)



Ticker code: ASX:SNT

ASX:SNT Red Flags & Risk Indicators
⚠️ RED FLAGS: 4 identified

  • Negative Operating Cash Flow
  • Low Operating Margin
  • Risk Of Capital Raise
  • Falling EBITDA Margins

Income Statement
Revenue 2024 Per Share Revenue 2025e Per Share Revenue 2026e Per Share Revenue 24 to 25e [%] Revenue 25e to 26e [%] EBITDA 2024 Per Share EBITDA 2025e Per Share EBITDA 2026e Per Share EBITDA 24 to 25e [%] EBITDA 25e to 26e [%]
0.0049 0.00187 None -61.9 None -0.0127 -0.00833 -0.0083 34.4 0.4
ASX:SNT Revenue Per Share (2012–2027)
CRISPR Therapeutics AG (ASX:SNT) Revenue Chart 2012–2027
ASX:SNT Earnings before Interest, Tax, Depreciation and Amortisation (EBITDA) Per Share (2012–2027)
✅✅
CRISPR Therapeutics AG (ASX:SNT) EBITDA Chart 2012–2027
ASX:SNT Normalised Earnings Per Share (EPS) (2012–2027)
CRISPR Therapeutics AG (ASX:SNT) Normalised EPS Chart (2012–2027)

Valuation
Price To Sales Price To Book PER 2023 PER 2024 13Y Median PER Low PER 2025e 13Y Median PER High PER 2026e Last Updated
5.4 2.4 -1.2 -2.4 5.0 -2.4 7.2 -2.4 21/4/25
ASX:SNT Yearly Price Earnings Ratio (PER) Highs and Lows
✅✅
CRISPR Therapeutics AG (ASX:SNT) PER Highs and Lows (2012–2027)
ASX:SNT Weekly Price Chart with Average True Range (ATR) Trailing Stop (10-Year View)
CRISPR Therapeutics AG (ASX:SNT) 10-Year Weekly ATR Trailing Stop Price Chart


Leave a Reply

Your email address will not be published. Required fields are marked *